MITOXANTRONE AND CYTOSINE-ARABINOSIDE AS 1ST-LINE INDUCTION THERAPY IN NEWLY-DIAGNOSED ACUTE NONLYMPHOCYTIC LEUKEMIA


ULKU B., AKTUGLU G., ZISSIS N., ULUTIN O.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, cilt.55, ss.552-558, 1994 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 55 Konu: 5
  • Basım Tarihi: 1994
  • Doi Numarası: 10.1016/s0011-393x(05)80186-9
  • Dergi Adı: CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
  • Sayfa Sayısı: ss.552-558

Özet

Thirty-three patients (22 men and 11 women; median age, 44 years) with newly diagnosed acute nonlymphocytic leukemia (ANLL) were treated with a combination of mitoxantrone, an anthracenedione derivative, 10 mg/m2/d for 3 days, plus cytosine arabinoside (ara-c), 100 mg/m2/d for 7 days. Patients not responding after two courses of therapy were considered treatment failures. Responding patients received two consolidation courses. Complete remission was achieved in 24 patients (73%) half of whom responded after a single course of therapy. Two patients were refractory and 7 died due to bone marrow depression. The median disease-free survival was 390 days, and the median overall survival was 450 days; 2 patients were still alive after 979 and 1166 days, respectively. Apart from hematologic findings, the most commonly observed toxicities were nausea/vomiting, alopecia, and infection. Mitoxantrone combined with ara-c is an effective and safe combination in the treatment of newly diagnosed ANLL.